Thomas Guttuso
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Thomas Guttuso has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Rachel Shepherd
University at Buffalo
3 shared publicationsDaniel Sirica
University at Buffalo
2 shared publications- David Gordon Lichter
From the Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, NY
2 shared publications Karl Kieburtz
2 shared publicationsMichael P. McDermott
2 shared publicationsMurali Ramanathan
SUNY Buffalo, Clin & Translat Sci Inst, Jacobs Sch Med & Biomed Sci, Dept Pharmaceut Sci, Buffalo, NY USA
2 shared publications
Latest Publications
- Open Access
- 14 March 2026
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 20, 506-511
Lithium’s effects on serum neurofilament light in Parkinson’s disease: A post hoc analysis
- 14 March 2026
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 20, 506-511
Open AccessLithium’s effects on serum neurofilament light in Parkinson’s disease: A post hoc analysis
- Open Access
Lithium’s effects on serum neurofilament light in Parkinson’s disease
Background: Blood neurofilament light (NfL) is a disease-progression biomarker in Parkinson’s disease (PD). Objectives: To determine the effects of lithium therapy on serum NfL in PD. Methods: Frozen serum samples from 28 PD patients were assessed for serum NfL using the SIMOA platform at baseline and after 24-weeks of lithium therapy. Pairwise comparisons were performed using the Fisher-Pitman permutation test. Results: Median % changes in serum NfL were -12.8, -2.0 and 11.2 in three patient groups defined by serum lithium levels at week 24: “high lithium” (0.21-0.56mmol/L, n=10), “medium lithium” (0.14-0.20mmol/L, n=8) and “low lithium” (p =0.0001) and high and medium lithium ( p =0.0203) but not medium and low lithium groups ( p =0.0907). Conclusions: Lithium therapy achieving serum levels 0.21-0.56mmol/L significantly reduced serum NfL in PD, which strongly supports further clinical investigation of lithium’s potential disease-modifying effects in PD. Financial Disclosure: Thomas Guttuso, Jr. is the President and majority owner of e3 Pharmaceuticals, Inc., which manufactures a lithium aspartate dietary supplement. None of the other authors have any financial disclosures. Study Funding: This study was funded by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR001412 to the University at Buffalo.
Open AccessLithium’s effects on serum neurofilament light in Parkinson’s disease
Background: Blood neurofilament light (NfL) is a disease-progression biomarker in Parkinson’s disease (PD). Objectives: To determine the effects of lithium therapy on serum NfL in PD. Methods: Frozen serum samples from 28 PD patients were assessed for serum NfL using the SIMOA platform at baseline and after 24-weeks of lithium therapy. Pairwise comparisons were performed using the Fisher-Pitman permutation test. Results: Median % changes in serum NfL were -12.8, -2.0 and 11.2 in three patient groups defined by serum lithium levels at week 24: “high lithium” (0.21-0.56mmol/L, n=10), “medium lithium” (0.14-0.20mmol/L, n=8) and “low lithium” (p =0.0001) and high and medium lithium ( p =0.0203) but not medium and low lithium groups ( p =0.0907). Conclusions: Lithium therapy achieving serum levels 0.21-0.56mmol/L significantly reduced serum NfL in PD, which strongly supports further clinical investigation of lithium’s potential disease-modifying effects in PD. Financial Disclosure: Thomas Guttuso, Jr. is the President and majority owner of e3 Pharmaceuticals, Inc., which manufactures a lithium aspartate dietary supplement. None of the other authors have any financial disclosures. Study Funding: This study was funded by the National Center for Advancing Translational Sciences of the National Institutes of Health under award number UL1TR001412 to the University at Buffalo.
- Open Access
- 1 October 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (10) , e2436874
Lithium Aspartate for Long COVID Fatigue and Cognitive Dysfunction
Importance: Neurologic post–COVID-19 condition (PCC), or long COVID, symptoms of fatigue and cognitive dysfunction continue to affect millions of people who have been infected with SARS-CoV-2. There currently are no effective evidence-based therapies available for treating neurologic PCC.Objective: To assess the effects of lithium aspartate therapy on PCC fatigue and cognitive dysfunction.Design, Setting, and Participants: A randomized, double-blind, placebo-controlled trial (RCT) enrolling participants in a neurology clinic from November 28, 2022, to June 29, 2023, with 3 weeks of follow-up, was conducted. Subsequently, an open-label lithium dose-finding study with 6 weeks of follow-up was performed among the same participants enrolled in the RCT. Eligible individuals needed to report new, bothersome fatigue or cognitive dysfunction persisting for more than 4 weeks after a self-reported positive test for COVID-19, Fatigue Severity Scale-7 (FSS-7) or Brain Fog Severity Scale (BFSS) score of 28 or greater, Beck Depression Inventory-II score less than 29, and no history of a condition known to cause fatigue or cognitive dysfunction. All participants in the RCT were eligible for the dose-finding study, except for those who responded to the placebo. Intention-to-treat analysis was used.Intervention: Lithium aspartate, 10 to 15 mg/d, or identically appearing placebo for 3 weeks followed by open-label lithium aspartate, 10 to 15 mg/d, for 2 weeks. In the subsequent dose-finding study, open-label lithium aspartate dosages up to 45 mg/d for 6 weeks were given.Main Outcomes and Measures: Change in sum of FSS-7 and BFSS scores. The scores for each measure range from 7 to 49, with higher scores indicating more severe symptoms. Secondary outcomes included changes from baseline in the scores of additional questionnaires.Results: Fifty-two participants were enrolled (30 [58%] males; mean [SD] age, 58.54 [14.34] years) and 26 were randomized to treatment with lithium aspartate (10 females) and 26 to placebo (12 female). Two participants assigned to lithium aspartate were lost to follow-up and none withdrew. No adverse events were attributable to lithium therapy. There were no significant intergroup differences for the primary outcome (−3.6; 95% CI, −16.6 to 9.5; P = .59) or any secondary outcomes. Among 3 patients completing a subsequent dose-finding study, open-label lithium aspartate, 40 to 45 mg/d, was associated with numerically greater reductions in fatigue and cognitive dysfunction scores than 15 mg/d, particularly in 2 patients with serum lithium levels of 0.18 and 0.49 mEq/L compared with 1 patient with a level of 0.10 mEq/L.Conclusions and Relevance: In this RCT, therapy with lithium aspartate, 10 to 15 mg/d, was ineffective for neurologic PCC fatigue and cognitive dysfunction. Another RCT is required to assess the potential benefits of higher lithium dosages for treating neurologic PCC.Trial Registration: ClinicalTrials.gov Identifier: NCT05618587 and NCT06108297
- 1 October 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (10) , e2436874
Open AccessLithium Aspartate for Long COVID Fatigue and Cognitive Dysfunction
Importance: Neurologic post–COVID-19 condition (PCC), or long COVID, symptoms of fatigue and cognitive dysfunction continue to affect millions of people who have been infected with SARS-CoV-2. There currently are no effective evidence-based therapies available for treating neurologic PCC.Objective: To assess the effects of lithium aspartate therapy on PCC fatigue and cognitive dysfunction.Design, Setting, and Participants: A randomized, double-blind, placebo-controlled trial (RCT) enrolling participants in a neurology clinic from November 28, 2022, to June 29, 2023, with 3 weeks of follow-up, was conducted. Subsequently, an open-label lithium dose-finding study with 6 weeks of follow-up was performed among the same participants enrolled in the RCT. Eligible individuals needed to report new, bothersome fatigue or cognitive dysfunction persisting for more than 4 weeks after a self-reported positive test for COVID-19, Fatigue Severity Scale-7 (FSS-7) or Brain Fog Severity Scale (BFSS) score of 28 or greater, Beck Depression Inventory-II score less than 29, and no history of a condition known to cause fatigue or cognitive dysfunction. All participants in the RCT were eligible for the dose-finding study, except for those who responded to the placebo. Intention-to-treat analysis was used.Intervention: Lithium aspartate, 10 to 15 mg/d, or identically appearing placebo for 3 weeks followed by open-label lithium aspartate, 10 to 15 mg/d, for 2 weeks. In the subsequent dose-finding study, open-label lithium aspartate dosages up to 45 mg/d for 6 weeks were given.Main Outcomes and Measures: Change in sum of FSS-7 and BFSS scores. The scores for each measure range from 7 to 49, with higher scores indicating more severe symptoms. Secondary outcomes included changes from baseline in the scores of additional questionnaires.Results: Fifty-two participants were enrolled (30 [58%] males; mean [SD] age, 58.54 [14.34] years) and 26 were randomized to treatment with lithium aspartate (10 females) and 26 to placebo (12 female). Two participants assigned to lithium aspartate were lost to follow-up and none withdrew. No adverse events were attributable to lithium therapy. There were no significant intergroup differences for the primary outcome (−3.6; 95% CI, −16.6 to 9.5; P = .59) or any secondary outcomes. Among 3 patients completing a subsequent dose-finding study, open-label lithium aspartate, 40 to 45 mg/d, was associated with numerically greater reductions in fatigue and cognitive dysfunction scores than 15 mg/d, particularly in 2 patients with serum lithium levels of 0.18 and 0.49 mEq/L compared with 1 patient with a level of 0.10 mEq/L.Conclusions and Relevance: In this RCT, therapy with lithium aspartate, 10 to 15 mg/d, was ineffective for neurologic PCC fatigue and cognitive dysfunction. Another RCT is required to assess the potential benefits of higher lithium dosages for treating neurologic PCC.Trial Registration: ClinicalTrials.gov Identifier: NCT05618587 and NCT06108297
- Open Access
- 7 May 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 14, 429-434
Lithium’s effects on therapeutic targets and MRI biomarkers in Parkinson’s disease: A pilot clinical trial
- 7 May 2023
- Published by Elsevier in IBRO Neuroscience Reports
- Vol. 14, 429-434
Open AccessLithium’s effects on therapeutic targets and MRI biomarkers in Parkinson’s disease: A pilot clinical trial
- 22 December 2021
- Published by Wiley in Movement Disorders
- Vol. 37 (3) , 490-501
Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's Disease
Background: Brain diffusion tensor imaging (DTI) has been shown to reflect cognitive changes in early Parkinson's disease (PD) but the diffusion‐based measure free water (FW) has not been previously assessed.Objectives: To assess if FW in the thalamic nuclei primarily involved with cognition (ie, the dorsomedial [DMN] and anterior [AN] nuclei), the nucleus basalis of Meynert (nbM), and the hippocampus correlates with and is associated with longitudinal cognitive decline and distinguishes cognitive status at baseline in early PD. Also, to explore how FW compares with conventional DTI, FW‐corrected DTI, and volumetric assessments for these outcomes.Methods: Imaging data and Montreal Cognitive Assessment (MoCA) scores from the Parkinson's Progression Markers Initiative database were analyzed using partial correlations and ANCOVA. Primary outcome multiple comparisons were corrected for false discovery rate (q value).Results: Thalamic DMN FW changes over 1 year correlated with MoCA changes over both 1 and 3 years (partial correlations −0.222, q = 0.040, n = 130; and − 0.229, q = 0.040, n = 123, respectively; mean PD duration at baseline = 6.85 months). NbM FW changes over 1 year only correlated with MoCA changes over 3 years (−0.222, q = 0.040). Baseline hippocampal FW was associated with cognitive impairment at 3 years (q = 0.040) and baseline nbM FW distinguished PD‐normal cognition (MoCA ≥26) from PD‐cognitive impairment (MoCA ≤25), (q = 0.008). The exploratory comparisons showed FW to be the most robust assessment modality for all outcomes.Conclusions: Thalamic DMN FW is a promising cognition progression biomarker in early PD that may assist in identifying cognition protective therapies in clinical trials. FW is a robust assessment modality for these outcomes. © 2021 International Parkinson and Movement Disorder Society
- 22 December 2021
- Published by Wiley in Movement Disorders
- Vol. 37 (3) , 490-501
Thalamic Dorsomedial Nucleus Free Water Correlates with Cognitive Decline in Parkinson's Disease
Background: Brain diffusion tensor imaging (DTI) has been shown to reflect cognitive changes in early Parkinson's disease (PD) but the diffusion‐based measure free water (FW) has not been previously assessed.Objectives: To assess if FW in the thalamic nuclei primarily involved with cognition (ie, the dorsomedial [DMN] and anterior [AN] nuclei), the nucleus basalis of Meynert (nbM), and the hippocampus correlates with and is associated with longitudinal cognitive decline and distinguishes cognitive status at baseline in early PD. Also, to explore how FW compares with conventional DTI, FW‐corrected DTI, and volumetric assessments for these outcomes.Methods: Imaging data and Montreal Cognitive Assessment (MoCA) scores from the Parkinson's Progression Markers Initiative database were analyzed using partial correlations and ANCOVA. Primary outcome multiple comparisons were corrected for false discovery rate (q value).Results: Thalamic DMN FW changes over 1 year correlated with MoCA changes over both 1 and 3 years (partial correlations −0.222, q = 0.040, n = 130; and − 0.229, q = 0.040, n = 123, respectively; mean PD duration at baseline = 6.85 months). NbM FW changes over 1 year only correlated with MoCA changes over 3 years (−0.222, q = 0.040). Baseline hippocampal FW was associated with cognitive impairment at 3 years (q = 0.040) and baseline nbM FW distinguished PD‐normal cognition (MoCA ≥26) from PD‐cognitive impairment (MoCA ≤25), (q = 0.008). The exploratory comparisons showed FW to be the most robust assessment modality for all outcomes.Conclusions: Thalamic DMN FW is a promising cognition progression biomarker in early PD that may assist in identifying cognition protective therapies in clinical trials. FW is a robust assessment modality for these outcomes. © 2021 International Parkinson and Movement Disorder Society
- 1 November 2021
- Published by Wiley in Movement Disorders
- Vol. 37 (2) , 325-333
Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo‐Controlled Trial of Rasagiline
Background: Rasagiline has received attention as a potential disease‐modifying therapy for Parkinson's disease (PD). Whether rasagiline is disease modifying remains in question.Objective: The main objective of this study was to determine whether rasagiline has disease‐modifying effects in PD over 1 year. Secondarily we evaluated two diffusion magnetic resonance imaging pulse sequences to determine the best sequence to measure disease progression.Methods: This prospective, randomized, double‐blind, placebo‐controlled trial assessed the effects of rasagiline administered at 1 mg/day over 12 months in early‐stage PD. The primary outcome was 1‐year change in free‐water accumulation in posterior substantia nigra (pSN) measured using two diffusion magnetic resonance imaging pulse sequences, one with a repetition time (TR) of 2500 ms (short TR; n = 90) and one with a TR of 6400 ms (long TR; n = 75). Secondary clinical outcomes also were assessed.Results: Absolute change in pSN free‐water accumulation was not significantly different between groups (short TR: P = 0.346; long TR: P = 0.228). No significant differences were found in any secondary clinical outcomes between groups. Long TR, but not short TR, data show pSN free‐water increased significantly over 1 year (P = 0.025). Movement Disorder Society Unified Parkinson's Disease Rating Scale testing of motor function, Part III increased significantly over 1 year (P = 0.009), and baseline free‐water in the pSN correlated with the 1‐year change in Movement Disorder Society Unified Parkinson's Disease Rating Scale testing of motor function, Part III (P = 0.004) and 1‐year change in bradykinesia score (P = 0.044).Conclusions: We found no evidence that 1 mg/day rasagiline has a disease‐modifying effect in PD over 1 year. We found pSN free‐water increased over 1 year, and baseline free‐water relates to clinical motor progression, demonstrating the importance of diffusion imaging parameters for detecting and predicting PD progression. © 2021 International Parkinson and Movement Disorder Society
- 1 November 2021
- Published by Wiley in Movement Disorders
- Vol. 37 (2) , 325-333
Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo‐Controlled Trial of Rasagiline
Background: Rasagiline has received attention as a potential disease‐modifying therapy for Parkinson's disease (PD). Whether rasagiline is disease modifying remains in question.Objective: The main objective of this study was to determine whether rasagiline has disease‐modifying effects in PD over 1 year. Secondarily we evaluated two diffusion magnetic resonance imaging pulse sequences to determine the best sequence to measure disease progression.Methods: This prospective, randomized, double‐blind, placebo‐controlled trial assessed the effects of rasagiline administered at 1 mg/day over 12 months in early‐stage PD. The primary outcome was 1‐year change in free‐water accumulation in posterior substantia nigra (pSN) measured using two diffusion magnetic resonance imaging pulse sequences, one with a repetition time (TR) of 2500 ms (short TR; n = 90) and one with a TR of 6400 ms (long TR; n = 75). Secondary clinical outcomes also were assessed.Results: Absolute change in pSN free‐water accumulation was not significantly different between groups (short TR: P = 0.346; long TR: P = 0.228). No significant differences were found in any secondary clinical outcomes between groups. Long TR, but not short TR, data show pSN free‐water increased significantly over 1 year (P = 0.025). Movement Disorder Society Unified Parkinson's Disease Rating Scale testing of motor function, Part III increased significantly over 1 year (P = 0.009), and baseline free‐water in the pSN correlated with the 1‐year change in Movement Disorder Society Unified Parkinson's Disease Rating Scale testing of motor function, Part III (P = 0.004) and 1‐year change in bradykinesia score (P = 0.044).Conclusions: We found no evidence that 1 mg/day rasagiline has a disease‐modifying effect in PD over 1 year. We found pSN free‐water increased over 1 year, and baseline free‐water relates to clinical motor progression, demonstrating the importance of diffusion imaging parameters for detecting and predicting PD progression. © 2021 International Parkinson and Movement Disorder Society
- 26 September 2021
- Published by Wiley in Movement Disorders
- Vol. 37 (1) , 70-79
Molecular Features of Parkinson's Disease in Patient‐Derived Midbrain Dopaminergic Neurons
Background: Despite intense efforts to develop an objective diagnostic test for Parkinson's disease, there is still no consensus on biomarkers that can accurately diagnose the disease.Objective: Identification of biomarkers for idiopathic Parkinson's disease (PD) may enable accurate diagnosis of the disease. We tried to find molecular and cellular differences in dopaminergic (DA) neurons derived from healthy subjects and idiopathic PD patients with or without rest tremor at onset.Methods: We measured the expression of genes controlling dopamine synthesis, sequestration, and catabolism as well as the levels of corresponding metabolites and reactive oxygen species in midbrain DA neurons differentiated from induced pluripotent stem cells (iPSCs) of healthy subjects and PD patients with or without rest tremor.Results: Significant differences in DA‐related gene expression, metabolites, and oxidative stress were found between midbrain DA neurons derived from healthy subjects and patients with PD. DA neurons derived from PD patients with or without rest tremor at onset exhibited significant differences in the levels of some of these transcripts, metabolites, and oxidative stress.Conclusion: The unique combination of these quantifiable molecular and cellular traits in iPSC‐derived midbrain DA neurons can distinguish healthy subjects from idiopathic PD patients and segregate PD patients with or without rest tremor at onset. The strategy may be used to develop an objective diagnostic test for PD.
- 26 September 2021
- Published by Wiley in Movement Disorders
- Vol. 37 (1) , 70-79
Molecular Features of Parkinson's Disease in Patient‐Derived Midbrain Dopaminergic Neurons
Background: Despite intense efforts to develop an objective diagnostic test for Parkinson's disease, there is still no consensus on biomarkers that can accurately diagnose the disease.Objective: Identification of biomarkers for idiopathic Parkinson's disease (PD) may enable accurate diagnosis of the disease. We tried to find molecular and cellular differences in dopaminergic (DA) neurons derived from healthy subjects and idiopathic PD patients with or without rest tremor at onset.Methods: We measured the expression of genes controlling dopamine synthesis, sequestration, and catabolism as well as the levels of corresponding metabolites and reactive oxygen species in midbrain DA neurons differentiated from induced pluripotent stem cells (iPSCs) of healthy subjects and PD patients with or without rest tremor.Results: Significant differences in DA‐related gene expression, metabolites, and oxidative stress were found between midbrain DA neurons derived from healthy subjects and patients with PD. DA neurons derived from PD patients with or without rest tremor at onset exhibited significant differences in the levels of some of these transcripts, metabolites, and oxidative stress.Conclusion: The unique combination of these quantifiable molecular and cellular traits in iPSC‐derived midbrain DA neurons can distinguish healthy subjects from idiopathic PD patients and segregate PD patients with or without rest tremor at onset. The strategy may be used to develop an objective diagnostic test for PD.
- 1 January 2021
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 3 (1) , 100273
Effect of gabapentin on hyperemesis gravidarum: a double-blind, randomized controlled trial
- 1 January 2021
- Published by Elsevier in American Journal of Obstetrics & Gynecology MFM
- Vol. 3 (1) , 100273
Effect of gabapentin on hyperemesis gravidarum: a double-blind, randomized controlled trial
- 1 October 2019
- Published by Elsevier in Medical Hypotheses
- Vol. 131, 109302
High lithium levels in tobacco may account for reduced incidences of both Parkinson’s disease and melanoma in smokers through enhanced β-catenin-mediated activity
- 1 October 2019
- Published by Elsevier in Medical Hypotheses
- Vol. 131, 109302
High lithium levels in tobacco may account for reduced incidences of both Parkinson’s disease and melanoma in smokers through enhanced β-catenin-mediated activity
- 1 July 2019
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 402, 121-130
Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium
- 1 July 2019
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 402, 121-130
Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium